Alembic Pharma gets tentative USFDA’s nod for breast cancer drug

01 Apr 2024 Evaluate

Alembic Pharmaceuticals has received tentative approval for generic Ribociclib tablets used in the treatment of breast cancer in the March quarter. The tentative approval by the US Food & Drug Administration (USFDA) was for Ribociclib tablets of strength 200 mg. 

The medicine is indicated for the treatment of adult patients with a certain type of advanced or metastatic breast cancer in a combination of drug therapy. It is the generic equivalent of Novartis' Kisqali tablets.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

775.30 -13.90 (-1.76%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×